Matching-Adjusted Indirect Comparison of Amivantamab vs Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer

Tae Min Kim1 Hemato-Oncology and Medical Oncology Center, Seoul National University Hospital, Seoul, 03080, Korea

Nicolas Girard2 Medical Oncology, Institut Curie, Institut du Thorax Curie-Montsouris, Paris cedex 05, 75248, France

Natasha B Leighl3 Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada

Joshua Sabari4 Medical Oncology, New York University Langone Health, New York, NY 10016, USA

Nora Rahhali5 Janssen Cilag, Île-de-France, 92787, France

Claudio A Schioppa6 Janssen Pharmaceutica NV, Beerse, B-2340, Belgium

Joris Diels6 Janssen Pharmaceutica NV, Beerse, B-2340, Belgium

Jan Sermon6 Janssen Pharmaceutica NV, Beerse, B-2340, Belgium

Conor Chandler7 Evidence Synthesis, Modeling & Communication, Evidera, Waltham, MA 02451, USA

Venediktos Kapetanakis8 Evidence Synthesis, Modeling & Communication, Evidera, London, W6 8BJ, UK

Ruhee Jain9 Janssen R&D, Raritan, NJ 08869, USA

Tracy Li9 Janssen R&D, Raritan, NJ 08869, USA

Suzy Van Sanden6 Janssen Pharmaceutica NV, Beerse, B-2340, BelgiumCorrespondence[email protected]

Your download is now in progress and you may close this window